PD thyroid cancers are rare, of follicular origin, often iodine unresponsive, and can be addressed with surgery and postop RT. More advanced disease presentation is a much larger issue and DM rates are as high as 60% with poor response to systemic therapy to date. Unlike anaplastic thyroid cancers...

I published in 2010 on 10 patients with different histologies on the RT for the thyroid (excluding anaplastic cases) ca cases. Below is the link to the paper. (https://www.researchgate.net/publication/232271428_Intensity_Modulated_Radiation_Therapy_IMRT_for_Thyroid_Cancer) (http://www.thyroidscien...

I agree with Dr. @Pollock. Targeted medical therapy has changed how we manage PDTC in recent years, with most patients being referred to oncology. The rapidly increasing knowledge about the molecular characteristics of PTDC will likely improve future therapies and guide management. As pointed out b...